Abstract:Bile acids are soluble derivatives of cholesterol produced in the liver that subsequently undergo bacterial transformation yielding a diverse array of metabolites. The bulk of bile acid synthesis takes place in the liver yielding primary bile acids; however, other tissues have also the capacity to generate bile acids (e.g. ovaries). Hepatic bile acids are then transported to bile and are subsequently released into the intestines. In the large intestine, a fraction of primary bile acids is converted to secondary bile acids by gut bacteria. The majority of the intestinal bile acids undergo reuptake and return to the liver. A small fraction of secondary and primary bile acids remains in the circulation and exert receptor-mediated and pure chemical effects (e.g. acidic bile in oesophageal cancer) on cancer cells. In this review, we assess how changes to bile acid biosynthesis, bile acid flux and local bile acid concentration modulate the behavior of different cancers. Here, we present in-depth the involvement of bile acids in oesophageal, gastric, hepatocellular, pancreatic, colorectal, breast, prostate, ovarian cancer. Previous studies often used bile acids in supraphysiological concentration, sometimes in concentrations 1000 times higher than the highest reported tissue or serum concentrations likely eliciting unspecific effects, a practice that we advocate against in this review. Furthermore, we show that, although bile acids were classically considered as pro-carcinogenic agents (e.g. oesophageal cancer), the dogma that switch, as lower concentrations of bile acids that correspond to their serum or tissue reference concentration possess anticancer activity in a subset of cancers. Differences in the response of cancers to bile acids lie in the differential expression of bile acid receptors between cancers (e.g. FXR vs. TGR5). UDCA, a bile acid that is sold as a generic medication against cholestasis or biliary surge, and its conjugates were identified with almost purely anticancer features suggesting a possibility for drug repurposing. Taken together, bile acids were considered as tumor inducers or tumor promoter molecules; nevertheless, in certain cancers, like breast cancer, bile acids in their reference concentrations may act as tumor suppressors suggesting a Janus-faced nature of bile acids in carcinogenesis.

Research progress for bile acids with its recptors in hepatocellular carcinoma

Bile Acids and Liver Cancer: Molecular Mechanism and Therapeutic Prospects

Advance in the research on several nuclear receptors related to bile acid metabolism

Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma

Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions

Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers

The gut microbiome-bile acid axis in hepatocarcinogenesis

Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma

Research progress on the role of cholesterol in hepatocellular carcinoma

The anticancer activity of bile acids in drug discovery and development

The regulatory role of bile acid microbiota in the progression of liver cirrhosis

A High Hepatic Uptake of Conjugated Bile Acids Promotes Colorectal Cancer—Associated Liver Metastasis

Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway.

The role of bile acids in carcinogenesis

Impact of Bile Acids on the Growth of Human Cholangiocarcinoma Via FXR

Advance of Study on Bile Acids in Barrett's Carcinogenesis

A high bile acid environment promotes apoptosis and inhibits migration in pancreatic cancer

Targeting bile acid signaling for the treatment of liver diseases: From bench to bed

Application of quantum descriptors for predicting adsorption performance of starch and cyclodextrin adsorbents.

Bile acid-mediated signaling in cholestatic liver diseases

Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment